These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30713370)

  • 21. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases.
    Dresen RC; De Vuysere S; De Keyzer F; Van Cutsem E; Prenen H; Vanslembrouck R; De Hertogh G; Wolthuis A; D'Hoore A; Vandecaveye V
    Cancer Imaging; 2019 Jan; 19(1):1. PubMed ID: 30616608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
    Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
    Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
    Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
    Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
    Sasamori H; Uno K; Wu J
    Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of ultrasound, ¹⁸F-FDG-PET/CT, and fused ¹⁸F-FDG-PET-MR images with DWI for the detection of cervical lymph node metastases of HNSCC.
    Heusch P; Sproll C; Buchbender C; Rieser E; Terjung J; Antke C; Boeck I; Macht S; Scherer A; Antoch G; Heusner TA; Handschel J
    Clin Oral Investig; 2014 Apr; 18(3):969-78. PubMed ID: 23892450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography or computed tomography in patients with gastrointestinal cancer.
    Gong J; Cao W; Zhang Z; Deng Y; Kang L; Zhu P; Liu Z; Zhou Z
    Gastroenterol Rep (Oxf); 2015 May; 3(2):128-35. PubMed ID: 25406465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
    Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
    Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study.
    Stecco A; Romano G; Negru M; Volpe D; Saponaro A; Costantino S; Sacchetti G; Inglese E; Alabiso O; Carriero A
    Radiol Med; 2009 Feb; 114(1):1-17. PubMed ID: 19082787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies.
    Grueneisen J; Schaarschmidt BM; Beiderwellen K; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
    J Nucl Med; 2014 Dec; 55(12):1930-5. PubMed ID: 25453042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
    Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
    Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
    Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
    World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MR evaluation of breast lesions obtained by diffusion-weighted imaging with background body signal suppression (DWIBS) and correlations with histological findings.
    Moschetta M; Telegrafo M; Rella L; Capolongo A; Stabile Ianora AA; Angelelli G
    Magn Reson Imaging; 2014 Jul; 32(6):605-9. PubMed ID: 24721005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.